Introduction

In March 2026, the global rare disease treatment landscape witnessed a wave of significant breakthroughs.

Approximately 20 rare disease-related drugs were approved worldwide, spanning hematology, neurology, immunology, and metabolism. These approvals cover conditions such as myasthenia gravis, multiple myeloma, Fabry disease, and spinal muscular atrophy.

Three major trends emerged:

• Accelerated innovation in mechanisms (bispecific antibodies, gene therapy)
• Greater precision targeting immune and metabolic pathways
• Improved convenience (oral and long-acting therapies)

These advancements are improving accessibility and long-term outcomes for patients worldwide.

---

Hematologic Diseases: From Supportive Care to Precision Modulation

1. Mitapivat (Agios Pharmaceuticals)
   Approved in the UAE for α- and β-thalassemia-related anemia. Improves red blood cell metabolism and reduces transfusion dependence.

2. Lomitapide (Chiesi Group)
   Approved in the U.S. for homozygous familial hypercholesterolemia. Reduces LDL-C by inhibiting lipoprotein production.

3. Herombopag Olamine (Hengrui Medicine)
   Approved in China for aplastic anemia. Stimulates hematopoiesis.

4. Dalnacogene Ponparvovec (Belief BioMed)
   Approved in Macao for hemophilia B. A gene therapy improving coagulation factor stability.

5. Fibrinogen Concentrate (Japan Blood Products Organization)
   Approved in Japan for congenital fibrinogen deficiency.

6. Vitamin K1 (Cheplapharm)
   Approved in China for coagulation disorders.

👉 Trend: Shift from replacement therapies to mechanism-driven targeted treatments.

---

Oncology and Immunology: Bispecifics and Targeted Therapies

1. Talquetamab (Johnson & Johnson)
   Approved for relapsed/refractory multiple myeloma. Redirects T cells to tumor cells.

2. Daratumumab (SC formulation)
   Improves administration efficiency and patient experience.

3. Dupilumab (Sanofi)
   Approved for bullous pemphigoid, targeting IL-4/IL-13 pathways.

4. Leniolisib (Pharming Group)
   Targets PI3K-delta pathway in APDS.

5. Selumetinib (AstraZeneca)
   Approved for NF1-related tumors.

6. Inebilizumab (Hansoh Pharma)
   Targets CD19 for myasthenia gravis.

👉 Trend: Immune modulation and precision targeting dominate innovation.

---

Metabolic and Genetic Disorders

1. Glycerol Phenylbutyrate (Immedica)
   Oral therapy reducing ammonia levels in urea cycle disorders.

2. Pegunigalsidase Alfa (Protalix)
   Long-acting enzyme replacement for Fabry disease.

3. Triheptanoin (Ultragenyx)
   Provides alternative energy metabolism support.

4. Calcium Folinate (Wellcovorin, GSK)
   Treats cerebral folate deficiency.

👉 Trend: Transition toward metabolic reprogramming strategies.

---

Neurology and Gene Therapy

1. Tividenofusp Alfa (Denali Therapeutics)
   Crosses the blood-brain barrier for Hunter syndrome.

2. Marnetegrane Autotemcel (Rocket Pharma)
   One-time gene therapy with curative potential.

3. Nusinersen (Biogen)
   Expands SMA treatment via SMN2 modulation.

4. Kyggevi (UCB)
   Targets mitochondrial DNA depletion disorders.

👉 Trend: Moving from symptom control to potential cures.

---

Conclusion: Entering the Era of Precision Medicine

March 2026 approvals highlight a clear evolution:

• Mechanisms: From replacement → gene correction & immune targeting
• Clinical outcomes: From short-term → long-term disease control
• Therapy formats: From hospital-based → oral & long-acting

Rare diseases are transitioning from untreatable to manageable conditions.

As innovation accelerates, global access and supply chain efficiency will become increasingly critical.

DengYueMed will continue to track global rare disease advancements and support the accessibility of innovative therapies worldwide.

---